Mednax Inc. (MD) Position Raised by GW Henssler & Associates Ltd.
GW Henssler & Associates Ltd. raised its position in shares of Mednax Inc. (NYSE:MD) by 4.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 143,378 shares of the company’s stock after buying an additional 6,171 shares during the period. GW Henssler & Associates Ltd. owned approximately 0.16% of Mednax worth $10,385,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Morgan Dempsey Capital Management LLC increased its position in Mednax by 147.7% in the second quarter. Morgan Dempsey Capital Management LLC now owns 2,192 shares of the company’s stock worth $159,000 after buying an additional 1,307 shares during the last quarter. Montag & Caldwell LLC increased its position in Mednax by 0.5% in the second quarter. Montag & Caldwell LLC now owns 12,900 shares of the company’s stock worth $934,000 after buying an additional 60 shares in the last quarter. Papp L Roy & Associates increased its position in Mednax by 12.2% in the second quarter. Papp L Roy & Associates now owns 11,483 shares of the company’s stock worth $832,000 after buying an additional 1,245 shares in the last quarter. Rice Hall James & Associates LLC increased its position in Mednax by 3.0% in the second quarter. Rice Hall James & Associates LLC now owns 28,160 shares of the company’s stock worth $2,040,000 after buying an additional 833 shares in the last quarter. Finally, Pitcairn Co. increased its position in Mednax by 33.0% in the second quarter. Pitcairn Co. now owns 6,524 shares of the company’s stock worth $472,000 after buying an additional 1,617 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.
Mednax Inc. (NYSE:MD) traded down 0.98% during mid-day trading on Friday, hitting $65.51. The stock had a trading volume of 482,563 shares. The stock has a market cap of $6.04 billion, a price-to-earnings ratio of 18.28 and a beta of 0.54. The company has a 50-day moving average of $65.73 and a 200-day moving average of $68.32. Mednax Inc. has a 12-month low of $61.40 and a 12-month high of $83.19.
Mednax (NYSE:MD) last released its quarterly earnings results on Thursday, July 28th. The company reported $1.03 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.07 by $0.04. Mednax had a return on equity of 14.88% and a net margin of 11.17%. The business earned $772 million during the quarter, compared to analyst estimates of $775.68 million. During the same quarter last year, the firm posted $0.90 EPS. The company’s revenue was up 14.1% compared to the same quarter last year. On average, analysts anticipate that Mednax Inc. will post $4.14 earnings per share for the current fiscal year.
A number of research analysts recently issued reports on MD shares. Zacks Investment Research upgraded Mednax from a “hold” rating to a “buy” rating and set a $80.00 price target on the stock in a research note on Wednesday, June 29th. Mizuho restated a “buy” rating and set a $79.00 price target on shares of Mednax in a research note on Tuesday, September 20th. Jefferies Group dropped their price target on Mednax from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Friday, August 26th. Citigroup Inc. dropped their price target on Mednax from $76.00 to $72.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 17th. Finally, JPMorgan Chase & Co. dropped their price target on Mednax from $85.00 to $80.00 and set an “overweight” rating on the stock in a research note on Friday, July 29th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $76.11.
In related news, Director Md Pascal J. Goldschmidt sold 1,500 shares of the business’s stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $65.01, for a total value of $97,515.00. Following the transaction, the director now owns 12,755 shares in the company, valued at $829,202.55. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.40% of the stock is owned by corporate insiders.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Stock Ratings for Mednax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc. and related stocks with our FREE daily email newsletter.